BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
Kemas kini terakhir: 2 hari lalu, 4:33PM31.37
-2.70 (-7.92%)
| Penutupan Terdahulu | 34.07 |
| Buka | 33.39 |
| Jumlah Dagangan | 3,982,505 |
| Purata Dagangan (3B) | 3,077,414 |
| Modal Pasaran | 5,966,228,992 |
| Harga / Jualan (P/S) | 28.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2025 - 5 May 2025 |
| Margin Keuntungan | -241.44% |
| Margin Operasi (TTM) | -3,762.90% |
| EPS Cair (TTM) | -2.88 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 237.10% |
| Nisbah Semasa (MRQ) | 4.67 |
| Aliran Tunai Operasi (OCF TTM) | -520.73 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -288.27 M |
| Pulangan Atas Aset (ROA TTM) | -47.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | BridgeBio Pharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 5.48% |
| % Dimiliki oleh Institusi | 91.15% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 31 Dec 2024 | 25,260,971 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 95.00 (Cantor Fitzgerald, 202.84%) | Beli |
| Median | 50.00 (59.39%) | |
| Rendah | 49.00 (Citigroup, 56.20%) | Beli |
| 49.00 (HC Wainwright & Co., 56.20%) | Beli | |
| Purata | 57.50 (83.30%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 35.65 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Redburn Atlantic | 31 Mar 2025 | 50.00 (59.39%) | Beli | 34.57 |
| JP Morgan | 24 Mar 2025 | 50.00 (59.39%) | Beli | 37.22 |
| Cantor Fitzgerald | 21 Feb 2025 | 95.00 (202.84%) | Beli | 36.85 |
| Citigroup | 21 Feb 2025 | 49.00 (56.20%) | Beli | 36.85 |
| Scotiabank | 21 Feb 2025 | 52.00 (65.76%) | Beli | 36.85 |
| 12 Feb 2025 | 49.00 (56.20%) | Beli | 31.95 | |
| HC Wainwright & Co. | 13 Feb 2025 | 49.00 (56.20%) | Beli | 31.56 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |